<DOC>
	<DOCNO>NCT00624936</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , azacytidine work different way stop growth cancer cell , either kill cell stop dividing . Bortezomib may stop growth cancer cell block blood flow cancer block enzyme need cell growth . Giving azacytidine together bortezomib may kill cancer cell . PURPOSE : This phase I trial study side effect best dose bortezomib give together azacytidine treat patient relapsed refractory acute myeloid leukemia myelodysplastic syndrome .</brief_summary>
	<brief_title>Azacytidine Bortezomib Treating Patients With Relapsed Refractory Acute Myeloid Leukemia Myelodysplastic Syndromes</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerate dose ( MTD ) bortezomib combination Azacytidine patient relapsed/refractory acute myeloid leukemia ( AML ) myelodysplastic syndrome ( MDS ) . - To define specific toxicity dose limit toxicity ( DLT ) Azacytidine plus bortezomib combination . Secondary - To determine overall response rate ( ORR ) . - To determine rate complete remission ( CR ) Azacytidine plus bortezomib relapsed/refractory AML MDS . - To correlate biological activity Azacytidine demethylating agent ( change target gene methylation gene expression , DNMT1 protein expression , global methylation ) clinical endpoint plasma pharmacokinetics azacytidine . - To characterize biological activity bortezomib potential demethylating agent . - To correlate intracellular concentration azacytidine-triphosphate global DNA methylation biological endpoint well clinical response . - To explore biologic role microRNAs determine clinical response azacytidine plus bortezomib combination achievement pharmacodynamic endpoint . OUTLINE : This dose-escalation study bortezomib . Patients receive azacytidine IV 30 minute day 1-7 bortezomib IV day 2 5 day 2 , 5 , 9 day 2 , 5 , 9 , 12 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos bortezomib tipifarnib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . After completion study treatment , patient follow least 30 day .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute myeloid leukemia ( AML ) myelodysplastic syndrome ( MDS ) High risk ( IPSS score ) Relapsed refractory disease Secondary AML therapy related disease ( tAML ) allow No active central nervous system disease granulocytic sarcoma sole site disease No advance malignant solid tumor PATIENT CHARACTERISTICS : Inclusion criterion : ECOG performance status 02 Life expectancy &gt; 6 month patient comorbid medical illness Total bilirubin &lt; 2.0mg/dL AST/ALT &lt; 2.5 time upper limit normal ( ULN ) Creatinine &lt; 2.0 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception prior study treatment Ability understand willingness sign write informed consent document Active infection allow provide control Exclusion criterion : History allergic reaction attribute compound similar chemical biologic composition azacytidine bortezomib easily manage Hypersensitivity bortezomib , boron , mannitol Uncontrolled intercurrent illness include , limited : Symptomatic congestive heart failure Unstable angina pectoris Serious cardiac arrhythmia Psychiatric illness/social situation would limit compliance study Myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV congestive heart failure Uncontrolled angina Severe uncontrolled ventricular arrhythmia Electrocardiographic evidence acute ischemia Active conduction system abnormalities ECG abnormality medically relevant Psychiatric condition prevent compliance protocol consent . Preexisting neuropathy grade 2 high serious neurologic toxicity would significantly increase risk complication bevacizumab therapy Serious medical psychiatric illness likely interfere participation clinical study Diagnosis treatment another malignancy within 3 year enrollment , exception following : Complete resect basal cell carcinoma Squamous cell carcinoma skin Any situ malignancy Lowrisk prostate cancer curative therapy PRIOR CONCURRENT THERAPY : Prior decitabine azacytidine MDS AML allow Prior bortezomib allow More 2 week since prior chemotherapy radiotherapy ( 6 week nitrosoureas mitomycin C ) More 14 day since prior concurrent investigational agent No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
</DOC>